CLAIMS

1. A compound of formula (I) or a salt thereof



(I)

wherein:

A represents pyridin-2-yl, pyridin-3-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-5-yl , 1,3-oxazol-2-yl, 1H-pyrazol-4-yl or isoxazol-4-yl or a group of formula (a) wherein * represents the point of attachment:

(a) 

wherein when A represents pyridin-3-yl, the pyridinyl ring may optionally be substituted at the 2 position by fluoro, methoxy or CH_2OH, at the 4 position by methyl or CH_2OH, or at the 5 position by fluoro; when A represents 1H-pyrazol-4-yl, the pyrazolyl ring may optionally be substituted at the 1 position by methyl, and where A represents isoxazol-4-yl, the isoxazolyl ring may optionally be substituted at the 3 position by methyl or at the 5 position by methyl;

R^1 represents halo, haloC_{1-3}alkyl, hydroxy, CN, $-O(CH_2)_2O(CH_2)_2NH_2$, -CNOH, $(O)_n(CH_2)_pR^{10}$, $-(CO)R^{10}$, R^{13}, $-(SO_2)R^{13}$, (C_{1-3}alkylene)$(CO)_qR^{14}$, $(CH=CH)(CO)R^{14}$, (C_{1-3}alkylene)$NHCOR^{14}$, -O-nitrogen containing monoheterocyclic ring with the proviso that the atom directly attached to the oxygen is not nitrogen, or a nitrogen containing heteroaryl ring, wherein the nitrogen containing monoheterocyclic ring is optionally substituted with one, two or three methyl groups and wherein the nitrogen containing heteroaryl ring is optionally substituted by one two or three groups selected from NH_2, (C_{1-3}alkylene)R^{13}, (C_{1-3}alkylene)$(CO)_qR^{14}$, C_{1-3}alkyl and halo;

n and q independently represent 0 or 1;

p represents 1, 2 or 3;

R^2, R^3, R^4, R^5 and R^6 independently represent hydrogen, halo, CN, C_{1-3}alkyl or C_{1-3}alkoxy;
R^7 and R^8 independently represent hydrogen or C_{1-2} alkyl;
R^9 represents hydrogen, halo, C_{1-2}alkyl, C_{1-2}alkoxy, $-CH_2CO_2H$ or $-CONHCH_3$;
R^{10} represents hydrogen, C_{1-3}alkyl, $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups;
R^{11} and R^{12} are independently selected from hydrogen and C_{1-3} alkyl, wherein said C_{1-3} alkyl group is optionally substituted with one, two or three halo, hydroxy, cyano or C_{1-2}alkoxy groups;
R^{13} represents $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups and wherein the nitrogen containing monoheterocyclic ring is attached via a nitrogen atom; and
R^{14} represents hydroxy or C_{1-3}alkoxy;
with the proviso that the compound of formula (I) is not:
2-[(phenylmethyl)oxy]-*N*-3-pyridinyl-5-(1-pyrrolidinylsulfonyl)benzamide;
2-{[(3,4-difluorophenyl)methyl]oxy}-5-(1-hydroxyethyl)-*N*-4-pyridazinylbenzamide;
5-bromo-2-(2-chlorobenzyloxy)-N-(pyridin-3-yl)benzamide;
5-chloro-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide;
5-bromo-*N*-{3-[(methylamino)carbonyl]phenyl}-2-[(phenylmethyl)oxy]benzamide; or
5-chloro-2-[(2-cyanophenyl)methoxy]-N-phenylbenzamide.

2. A compound of formula (I) or a salt thereof according to claim 1, wherein R^1 represents $-(O)_n(CH_2)_pR^{10}$ or $-(CO)R^{10}$ wherein R^{10} represents hydrogen, C_{1-3}alkyl, $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups and wherein n represents 0 or 1 and wherein p represents 1, 2 or 3.

3. A compound of formula (I) or a salt thereof according to claim 1 or claim 2, wherein one or two of R^2, R^3, R^4, R^5 and R^6 represent fluoro and the remaining groups represent hydrogen.

4. A compound of formula (I) or a salt thereof according to any one of claims 1 to 3, wherein R^2, R^3, R^5 and R^6 each represent hydrogen and R^4 represents fluoro.

5. A compound of formula (I) or a salt thereof according to any one of claims 1 to 4, wherein R^7 and R^8 each represent hydrogen.

6. A compound of formula (I) or a salt thereof according to any one of claims 1 to 5, wherein A represents pyridin-3-yl, wherein the pyridinyl ring may optionally be substituted at the 2 position by fluoro, pyridazin-4-yl, 1H-pyrazol-4-yl, wherein the pyrazolyl ring may optionally be substituted at the 1 position by methyl, or isoxazol-4-yl,

wherein the isoxazolyl ring may optionally be substituted at the 3 position by methyl or at the 5 position by methyl.

7. A compound of formula (I) or a salt thereof according to claim 1, wherein:
A represents pyridin-3-yl, pyridazin-4-yl, 1H-pyrazol-4-yl or isoxazol-4-yl, wherein when A represents pyridin-3-yl, the pyridinyl ring may optionally be substituted at the 2 position by fluoro; when A represents 1H-pyrazol-4-yl, the pyrazolyl ring may optionally be substituted at the 1 position by methyl ,and where A represents isoxazol-4-yl, the isoxazolyl ring may optionally be substituted at the 3 position by methyl or at the 5 position by methyl;
R^1 represents $-(O)_n(CH_2)_pR^{10}$, $-(CO)R^{10}$, R^{13}, $-(SO_2)R^{13}$ or a nitrogen containing heteroaryl ring which nitrogen containing heteroaryl ring is optionally substituted by one, two or three groups selected from NH_2, $(C_{1-3}alkylene)R^{13}$, $(C_{1-3}alkylene)(CO)_qR^{14}$, C_{1-3}alkyl and halo ;
R^2, R^3, R^4, R^5, R^6 independently represent hydrogen or fluoro;
R^7 and R^8 represent hydrogen;
R^{10} represents hydrogen, C_{1-3}alkyl, $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups;
R^{11} and R^{12} independently represent hydrogen or C_{1-3} alkyl;
R^{13} represents $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups and wherein the nitrogen containing monoheterocyclic ring is attached via a nitrogen atom;
R^{14} represents hydroxy or C_{1-3}alkoxy; and
n and q independently represent 0 or 1 and p represents 1, 2 or 3;
with the proviso that the compound of formula (I) is not 2-[(phenylmethyl)oxy]-*N*-3-pyridinyl-5-(1-pyrrolidinylsulfonyl)benzamide.

8. A compound of formula (I) or a salt thereof according to claim 1, which is a compound of examples 1 to 137 or a salt thereof.

9. A pharmaceutical composition which comprises the compound of formula (I) as defined in any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

10. A compound of formula (I) as defined in any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof for use in the treatment or prophylaxis of Parkinson's disease.

11. Use of a compound of formula (I) as defined in any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of Parkinson's disease.

12. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use as a medicament



(I)

wherein:

A represents pyridin-2-yl, pyridin-3-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-5-yl , 1,3-oxazol-2-yl, 1H-pyrazol-4-yl or isoxazol-4-yl or a group of formula (a) wherein * represents the point of attachment:

(a) 

wherein when A represents pyridin-3-yl, the pyridinyl ring may optionally be substituted at the 2 position by fluoro, methoxy or CH_2OH, at the 4 position by methyl or CH_2OH, or at the 5 position by fluoro; when A represents 1H-pyrazol-4-yl, the pyrazolyl ring may optionally be substituted at the 1 position by methyl, and where A represents isoxazol-4-yl, the isoxazolyl ring may optionally be substituted at the 3 position by methyl or at the 5 position by methyl;

R^1 represents halo, haloC_{1-3}alkyl, hydroxy, CN, $-O(CH_2)_2O(CH_2)_2NH_2$, -CNOH, $(O)_n(CH_2)_pR^{10}$, $-(CO)R^{10}$, R^{13}, $-(SO_2)R^{13}$, $(C_{1-3}$alkylene$)(CO)_qR^{14}$, $(CH{=}CH)(CO)R^{14}$, $(C_{1-3}$alkylene$)NHCOR^{14}$, -O-nitrogen containing monoheterocyclic ring with the proviso that the atom directly attached to the oxygen is not nitrogen, or a nitrogen containing heteroaryl ring, wherein the nitrogen containing monoheterocyclic ring is optionally substituted with one, two or three methyl groups and wherein the nitrogen containing heteroaryl ring is optionally substituted by one two or three groups selected from NH_2, $(C_{1-3}$alkylene$)R^{13}$, $(C_{1-3}$alkylene$)(CO)_qR^{14}$, C_{1-3}alkyl and halo;

n and q independently represent 0 or 1;

p represents 1, 2 or 3;

R^2, R^3, R^4, R^5 and R^6 independently represent hydrogen, halo, CN, C_{1-3}alkyl or C_{1-3}alkoxy;
R^7 and R^8 independently represent hydrogen or C_{1-2} alkyl;
R^9 represents hydrogen, halo, C_{1-2}alkyl, C_{1-2}alkoxy, $-CH_2CO_2H$ or $-CONHCH_3$;
R^{10} represents hydrogen, C_{1-3}alkyl, $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups;
R^{11} and R^{12} are independently selected from hydrogen and C_{1-3} alkyl, wherein said C_{1-3} alkyl group is optionally substituted with one, two or three halo, hydroxy, cyano or C_{1-2}alkoxy groups;
R^{13} represents $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups and wherein the nitrogen containing monoheterocyclic ring is attached via a nitrogen atom; and
R^{14} represents hydroxy or C_{1-3}alkoxy;
with the proviso that the compound of formula (I) is not:
2-[(phenylmethyl)oxy]-*N*-3-pyridinyl-5-(1-pyrrolidinylsulfonyl)benzamide; or
2-{[(3,4-difluorophenyl)methyl]oxy}-5-(1-hydroxyethyl)-*N*-4-pyridazinylbenzamide.

13. A compound of formula (I) as defined in claim 12 or a pharmaceutically acceptable salt thereof for use in the treatment or prophylaxis of Parkinson's disease.

14. A pharmaceutical composition for use in the treatment or prophylaxis of Parkinson's disease which comprises the compound of formula (I) as defined in claim 12 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

CLAIMS

1. A compound of formula (I) or a salt thereof



(I)

wherein:

A represents pyridin-2-yl, pyridin-3-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-5-yl , 1,3-oxazol-2-yl, 1H-pyrazol-4-yl or isoxazol-4-yl or a group of formula (a) wherein * represents the point of attachment:

(a) 

wherein when A represents pyridin-3-yl, the pyridinyl ring may optionally be substituted at the 2 position by fluoro, methoxy or CH_2OH, at the 4 position by methyl or CH_2OH, or at the 5 position by fluoro; when A represents 1H-pyrazol-4-yl, the pyrazolyl ring may optionally be substituted at the 1 position by methyl ,and where A represents isoxazol-4-yl, the isoxazolyl ring may optionally be substituted at the 3 position by methyl or at the 5 position by methyl;

R^1 represents halo, haloC_{1-3}alkyl, hydroxy, CN, $-O(CH_2)_2O(CH_2)_2NH_2$, -CNOH, $(O)_n(CH_2)_pR^{10}$, $-(CO)R^{10}$, R^{13}, $-(SO_2)R^{13}$, $(C_{1-3}$alkylene$)(CO)_qR^{14}$, $(CH{=}CH)(CO)R^{14}$, $(C_{1-3}$alkylene$)NHCOR^{14}$, -O-nitrogen containing monoheterocyclic ring with the proviso that the atom directly attached to the oxygen is not nitrogen, or a nitrogen containing heteroaryl ring, wherein the nitrogen containing monoheterocyclic ring is optionally substituted with one, two or three methyl groups and wherein the nitrogen containing heteroaryl ring is optionally substituted by one two or three groups selected from NH_2, $(C_{1-3}$alkylene$)R^{13}$, $(C_{1-3}$alkylene$)(CO)_qR^{14}$, C_{1-3}alkyl and halo;

n and q independently represent 0 or 1;

p represents 1, 2 or 3;

R^2, R^3, R^4, R^5 and R^6 independently represent hydrogen, halo, CN, C_{1-3}alkyl or C_{1-3}alkoxy;

R^7 and R^8 independently represent hydrogen or C_{1-2} alkyl;
R^9 represents hydrogen, halo, C_{1-2}alkyl, C_{1-2}alkoxy, $-CH_2CO_2H$ or $-CONHCH_3$;
R^{10} represents hydrogen, C_{1-3}alkyl, $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups;
R^{11} and R^{12} are independently selected from hydrogen and C_{1-3} alkyl, wherein said C_{1-3} alkyl group is optionally substituted with one, two or three halo, hydroxy, cyano or C_{1-2}alkoxy groups;
R^{13} represents $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups and wherein the nitrogen containing monoheterocyclic ring is attached via a nitrogen atom; and
R^{14} represents hydroxy or C_{1-3}alkoxy;
with the proviso that the compound of formula (I) is not:
2-[(phenylmethyl)oxy]-*N*-3-pyridinyl-5-(1-pyrrolidinylsulfonyl)benzamide;
2-{[(3,4-difluorophenyl)methyl]oxy}-5-(1-hydroxyethyl)-*N*-4-pyridazinylbenzamide;
5-bromo-2-(2-chlorobenzyloxy)-N-(pyridin-3-yl)benzamide;
5-chloro-2-[(phenylmethyl)oxy]-N-3-pyridinylbenzamide;
5-bromo-*N*-{3-[(methylamino)carbonyl]phenyl}-2-[(phenylmethyl)oxy]benzamide; or
5-chloro-2-[(2-cyanophenyl)methoxy]-N-phenylbenzamide;
and also is not 5-amino-2-(2,4-dimethylbenzyloxy)benzanilide.

2. A compound of formula (I) or salt thereof according to claim 1, wherein R^1 represents $-(O)_n(CH_2)_pR^{10}$ or $-(CO)R^{10}$ wherein R^{10} represents hydrogen, C_{1-3}alkyl, $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups and wherein n represents 0 or 1 and wherein p represents 1, 2 or 3.

3. A compound of formula (I) or a salt thereof according to claim 1 or claim 2, wherein one or two of R^2, R^3, R^4, R^5 and R^6 represent fluoro and the remaining groups represent hydrogen.

4. A compound of formula (I) or a salt thereof according to any one of claims 1 to 3, wherein R^2, R^3, R^5 and R^6 each represent hydrogen and R^4 represents fluoro.

5. A compound of formula (I) or a salt thereof according to any one of claims 1 to 4, wherein R^7 and R^8 each represent hydrogen.

6. A compound of formula (I) or a salt thereof according to any one of claims 1 to 5, wherein A represents pyridin-3-yl, wherein the pyridinyl ring may optionally be substituted at the 2 position by fluoro, pyridazin-4-yl, 1H-pyrazol-4-yl, wherein the pyrazolyl ring may optionally be substituted at the 1 position by methyl, or isoxazol-4-yl, wherein the isoxazolyl ring may optionally be substituted at the 3 position by methyl or at the 5 position by methyl.

7. A compound of formula (I) or a salt thereof according to claim 1, wherein:
A represents pyridin-3-yl-, pyridazin-4-yl, 1H-pyrazol-4-yl or isoxazol-4-yl, wherein when A represents pyridin-3-yl, the pyridinyl ring may optionally be substituted at the 2 position by fluoro; when A represents 1H-pyrazol-4-yl, the pyrazolyl ring may optionally be substituted at the 1 position by methyl, and where A represents isoxazol-4-yl, the isoxazolyl ring may optionally be substituted at the 3 position by methyl or at the 5 position by methyl;
R^1 represents $-(O)_n(CH_2)_pR^{10}$, $-(CO)R^{10}$, R^{13}, $-(SO_2)R^{13}$ or a nitrogen containing heteroaryl ring which nitrogen containing heteroaryl ring is optionally substituted by one, two or three groups selected from NH_2, $(C_{1-3}alkylene)R^{13}$, $(C_{1-3}alkylene)(CO)_qR^{14}$, $C_{1-3}alkyl$ and halo;
R^2, R^3, R^4, R^5,R^6 independently represent hydrogen or fluoro;
R^7 and R^8 represent hydrogen;
R^{10} represents hydrogen, $C_{1-3}alkyl$, $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups;
R^{11} and R^{12} independently represent hydrogen or C_{1-3} alkyl;
R^{13} represents $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups and wherein the nitrogen containing monoheterocyclic ring is attached via a nitrogen atom;
R^{14} represents hydroxy or $C_{1-3}alkoxy$; and
n and q independently represent 0 or 1 and p represents 1, 2 or 3;
with the proviso that the compound of formula (I) is not 2-[(phenylmethyl)oxy]-*N*-3-pyridinyl-5-(1-pyrrolidinylsulfonyl)benzamide.

8. A compound of formula (I) or a salt thereof according to claim 1, which is a compound of examples 1 to 137 or a salt thereof.

9. A pharmaceutical composition which comprises the compound of formula (I) as defined in any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

10. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use as a medicament



(I)

wherein:

A represents pyridin-2-yl, pyridin-3-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-5-yl , 1,3-oxazol-2-yl, 1H-pyrazol-4-yl or isoxazol-4-yl or a group of formula (a) wherein * represents the point of attachment:

(a) 

wherein when A represents pyridin-3-yl, the pyridinyl ring may optionally be substituted at the 2 position by fluoro, methoxy or CH_2OH, at the 4 position by methyl or CH_2OH, or at the 5 position by fluoro; when A represents 1H-pyrazol-4-yl, the pyrazolyl ring may optionally be substituted at the 1 position by methyl ,and where A represents isoxazol-4-yl, the isoxazolyl ring may optionally be substituted at the 3 position by methyl or at the 5 position by methyl;

R^1 represents halo, haloC_{1-3}alkyl, hydroxy, CN, $-O(CH_2)_2O(CH_2)_2NH_2$, -CNOH, $(O)_n(CH_2)_pR^{10}$, $-(CO)R^{10}$, R^{13}, $-(SO_2)R^{13}$, (C_{1-3}alkylene)$(CO)_qR^{14}$, $(CH=CH)(CO)R^{14}$, (C_{1-3}alkylene)$NHCOR^{14}$, -O-nitrogen containing monoheterocyclic ring with the proviso that the atom directly attached to the oxygen is not nitrogen, or a nitrogen containing heteroaryl ring, wherein the nitrogen containing monoheterocyclic ring is optionally substituted with one, two or three methyl groups and wherein the nitrogen containing heteroaryl ring is optionally substituted by one two or three groups selected from NH_2, (C_{1-3}alkylene)R^{13}, (C_{1-3}alkylene)$(CO)_qR^{14}$, C_{1-3}alkyl and halo;

n and q independently represent 0 or 1;

p represents 1, 2 or 3;

R^2, R^3, R^4, R^5 and R^6 independently represent hydrogen, halo, CN, C_{1-3}alkyl or C_{1-3}alkoxy;

R^7 and R^8 independently represent hydrogen or C_{1-2} alkyl;

R^9 represents hydrogen, halo, C_{1-2}alkyl, C_{1-2}alkoxy, $-CH_2CO_2H$ or $-CONHCH_3$;

R^{10} represents hydrogen, C_{1-3}alkyl, $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups;
R^{11} and R^{12} are independently selected from hydrogen and C_{1-3} alkyl, wherein said C_{1-3} alkyl group is optionally substituted with one, two or three halo, hydroxy, cyano or C_{1-2}alkoxy groups;
R^{13} represents $-NR^{11}R^{12}$, or a nitrogen containing monoheterocyclic ring which ring is optionally substituted with one, two or three methyl groups and wherein the nitrogen containing monoheterocyclic ring is attached via a nitrogen atom; and
R^{14} represents hydroxy or C_{1-3}alkoxy;
with the proviso that the compound of formula (I) is not:
2-[(phenylmethyl)oxy]-*N*-3-pyridinyl-5-(1-pyrrolidinylsulfonyl)benzamide; or
2-{[(3,4-difluorophenyl)methyl]oxy}-5-(1-hydroxyethyl)-*N*-4-pyridazinylbenzamide.

11. A compound of formula (I) as defined in claim 10 or a pharmaceutically acceptable salt thereof for use in the treatment or prophylaxis or Parkinson's disease.

12. A pharmaceutical composition for use in the treatment or prophylaxis of Parkinson's disease which comprises the compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.